חוב כולל להון NeuroMetrix (NURO)

NeuroMetrix, Inc. (NURO) is expanding the availability of Quell pain management systems through pharmacies and digital monitoring. This chart on GURU.Markets for the separate_debt_total_eq metric shows 0.01, while weak pricing power due to limited insurance coverage makes demand sensitive. The company generates revenue from the sale of neurostimulators and diagnostic equipment for clinics and individuals with neuropathy.

The Debt-to-Equity ratio measures the proportion of borrowed funds relative to shareholders' equity, allowing investors to assess financial leverage and the balance sheet's resilience to changes in Fed rates. Analyzing the balance between debt and equity helps filter out market noise to determine whether NeuroMetrix, Inc. (NURO) possesses sufficient resources to scale Quell device sales through pharmacy chains and implement digital monitoring platforms.